{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T15:25:39Z","timestamp":1785684339062,"version":"3.56.0"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:p>Vulvovaginal melanoma (VVM) is a rare but deadly disease, accounting for 5% of all vulvar malignancies, with a 5-yr survival rate of only 47% for all stages of the disease. VVM is a distinct subset of melanoma, with a unique genomic profile and underlying pathogenesis unassociated with sun exposure. Distinguishing these rare malignancies from very common pigmented lesions of the vulva and vagina is challenging as histologic features often overlap between entities. PReferentially expressed Antigen in MElanoma (PRAME) is a melanoma-associated protein, and immunohistochemistry (IHC) for PRAME distinguishes cutaneous, oral mucosal, and retinal melanoma from atypical nevi. Given the biological differences between VVM and cutaneous melanoma, the utility of PRAME IHC for the diagnosis of VVM is unknown. We accrued a cohort of 20 VVM and 21 benign vulvar melanocytic nevi. We found that nuclear PRAME IHC staining with 4+ intensity was present in 85% of the VVM and 0% of the nevi. With the assistance of PRAME IHC, we found evidence of close or positive margin involvement in 3 of 10 cases where margins were originally diagnosed as negative for melanoma in situ. Our study is the first to assess PRAME IHC in a cohort of VVM cases and provides confidence for using PRAME IHC to assist with diagnosis and margin assessment in this rare disease.<\/jats:p>","DOI":"10.1097\/pgp.0000000000001004","type":"journal-article","created":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T15:18:08Z","timestamp":1702394288000},"page":"389-396","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["PRAME Immunohistochemistry for Distinguishing Vulvar and Vaginal Melanoma From Benign Melanocytic Nevi"],"prefix":"10.1097","volume":"43","author":[{"given":"Spencer D.","family":"Martin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina C.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Blake","family":"Gilks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard I.","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lien N.","family":"Hoang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,12,6]]},"reference":[{"key":"R1-20260423","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s40257-021-00614-7","article-title":"Vulvar melanoma: molecular characteristics, diagnosis, surgical management, and medical treatment","volume":"22","author":"Wohlmuth","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"R2-20260423","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s40257-019-00487-x","article-title":"Malignant melanoma of the vulva and vagina: a US population-based study of 1863 patients","volume":"21","author":"Wohlmuth","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"R3-20260423","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1093\/annonc\/mdz411","article-title":"clinicalguidelines@esmo.org EGCEa. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-updagger","volume":"30","author":"Michielin","year":"2019","journal-title":"Ann Oncol"},{"key":"R4-20260423","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s00277-008-0514-8","article-title":"Aberrant hypomethylation of the cancer-testis antigen PRAME correlates with PRAME expression in acute myeloid leukemia","volume":"87","author":"Ortmann","year":"2008","journal-title":"Ann Hematol"},{"key":"R5-20260423","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1097\/PAS.0000000000001134","article-title":"PRAME expression in melanocytic tumors","volume":"42","author":"Lezcano","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"R6-20260423","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1309\/AJCPGA95KVSAUDMF","article-title":"PRAME (preferentially expressed antigen of melanoma) is a novel marker for differentiating serous carcinoma from malignant mesothelioma","volume":"137","author":"Brenne","year":"2012","journal-title":"Am J Clin Pathol"},{"key":"R7-20260423","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/CJI.0000000000000322","article-title":"WT1, PRAME, and PR3 mRNA expression in acute myeloid leukemia (AML)","volume":"43","author":"Steger","year":"2020","journal-title":"J Immunother"},{"key":"R8-20260423","first-page":"4090","article-title":"Heterogeneous expression of the tumor-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma: candidates for T-cell-based immunotherapies?","volume":"58","author":"Neumann","year":"1998","journal-title":"Cancer Res"},{"key":"R9-20260423","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/sj.bjc.6604494","article-title":"PRAME expression and clinical outcome of breast cancer","volume":"99","author":"Epping","year":"2008","journal-title":"Br J Cancer"},{"key":"R10-20260423","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1097\/PAS.0000000000001944","article-title":"PRAME expression in cancer. A systematic immunohistochemical study of >5800 epithelial and nonepithelial tumors","volume":"46","author":"Kaczorowski","year":"2022","journal-title":"Am J Surg Pathol"},{"key":"R11-20260423","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.cell.2005.07.003","article-title":"The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling","volume":"122","author":"Epping","year":"2005","journal-title":"Cell"},{"key":"R12-20260423","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.path.2021.01.001","article-title":"PRAME immunohistochemistry as an ancillary test for the assessment of melanocytic lesions","volume":"14","author":"Lezcano","year":"2021","journal-title":"Surg Pathol Clin"},{"key":"R13-20260423","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/cup.14361","article-title":"PRAME immunohistochemistry is useful in differentiating oral melanomas from nevi and melanotic macules","volume":"50","author":"Schmitt","year":"2023","journal-title":"J Cutan Pathol"},{"key":"R14-20260423","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1158\/1078-0432.CCR-15-2071","article-title":"PRAME as an independent biomarker for metastasis in uveal melanoma","volume":"22","author":"Field","year":"2016","journal-title":"Clin Cancer Res"},{"key":"R15-20260423","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1038\/s41379-019-0335-4","article-title":"Analyses of molecular and histopathologic features and expression of PRAME by immunohistochemistry in mucosal melanomas","volume":"32","author":"Toyama","year":"2019","journal-title":"Mod Pathol"},{"key":"R16-20260423","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/cncr.30473","article-title":"Vulvar and vaginal melanoma: a unique subclass of mucosal melanoma based on a comprehensive molecular analysis of 51 cases compared with 2253 cases of nongynecologic melanoma","volume":"123","author":"Hou","year":"2017","journal-title":"Cancer"},{"key":"R17-20260423","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jaad.2014.03.033","article-title":"Oncogenic mutations in melanomas and benign melanocytic nevi of the female genital tract","volume":"71","author":"Tseng","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"R18-20260423","doi-asserted-by":"crossref","first-page":"7900","DOI":"10.3390\/curroncol29100624","article-title":"Improving time-to-treatment for advanced non-small cell lung cancer patients through faster single gene EGFR testing using the Idylla EGFR testing platform","volume":"29","author":"Banyi","year":"2022","journal-title":"Curr Oncol"},{"key":"R19-20260423","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1111\/his.14312","article-title":"PRAME immunohistochemistry as an adjunct for diagnosis and histological margin assessment in lentigo maligna","volume":"78","author":"Gradecki","year":"2021","journal-title":"Histopathology"},{"key":"R20-20260423","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/his.14904","article-title":"Diagnostic test accuracy meta-analysis of PRAME in distinguishing primary cutaneous melanomas from benign melanocytic lesions","volume":"83","author":"Kunc","year":"2023","journal-title":"Histopathology"},{"key":"R21-20260423","doi-asserted-by":"crossref","first-page":"5123","DOI":"10.3390\/cancers14205123","article-title":"Cutaneous melanoma versus vulvovaginal melanoma-risk factors, pathogenesis and comparison of immunotherapy efficacy","volume":"14","author":"Lorenz","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R22-20260423","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1038\/modpathol.2013.211","article-title":"Comparison of molecular abnormalities in vulvar and vaginal melanomas","volume":"27","author":"Aulmann","year":"2014","journal-title":"Mod Pathol"},{"key":"R23-20260423","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1111\/his.14793","article-title":"Hyperplastic melanocytes with chromosomal aberrations in surrounding skin of subungual melanoma: fluorescence in situ hybridisation analysis using whole-slide digital imaging","volume":"81","author":"Shojiguchi","year":"2022","journal-title":"Histopathology"}],"container-title":["International Journal of Gynecological Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PGP.0000000000001004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:16Z","timestamp":1776988816000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PGP.0000000000001004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,6]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/pgp.0000000000001004","relation":{},"ISSN":["0277-1691"],"issn-type":[{"value":"0277-1691","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,6]]}}}